Medical School · Year 3 · Internal Medicine · includes a discussion video

Seminar 11: Pneumonia

Internal Medicine Clerkship

Learning Objectives

By the end of this seminar, students will be able to:

1. Classify pneumonia by acquisition setting (community-acquired, hospital-acquired, ventilator-associated) and differentiate typical from atypical presentations
2. Describe common causative pathogens and identify clinical risk factors that predispose to specific organisms
3. Apply validated severity assessment tools including CURB-65, PSI, and ATS/IDSA criteria to guide disposition decisions
4. Select appropriate empiric antibiotic therapy based on acquisition setting, severity, and patient risk factors
5. Describe the systematic approach to treatment failure, including differential diagnosis and workup
6. Recognize major complications of pneumonia including parapneumonic effusion, empyema, lung abscess, and ARDS

Seminar Outline

Section 1: Classification and Epidemiology

Pneumonia is classified primarily by the setting in which it is acquired, as this determines the likely pathogen spectrum and guides empiric antibiotic selection. Community-acquired pneumonia develops outside of the hospital setting in patients who have not been recently hospitalized. Hospital-acquired pneumonia is defined as pneumonia developing forty-eight hours or more after hospital admission, reflecting exposure to nosocomial pathogens and the altered host defenses associated with hospitalization. Ventilator-associated pneumonia develops forty-eight hours or more after endotracheal intubation and initiation of mechanical ventilation and carries a particularly high morbidity and mortality. The previously used category of healthcare-associated pneumonia has been removed from current guidelines, as studies showed that patients in this category did not consistently harbor multidrug-resistant organisms and the broad-spectrum empiric coverage it mandated led to unnecessary antibiotic exposure. Aspiration pneumonia represents a distinct entity associated with macro- or micro-aspiration events and is characterized by a unique microbiological profile.

The epidemiology of pneumonia underscores its importance as a leading cause of infectious morbidity and mortality worldwide. The incidence of community-acquired pneumonia ranges from five to eleven cases per one thousand adults per year, with significant seasonal variation and higher rates during winter months. Approximately twenty percent of patients with community-acquired pneumonia require hospitalization, and the severity spectrum ranges widely from mild illness manageable in the outpatient setting to fulminant disease requiring intensive care. Mortality varies dramatically by setting: outpatient community-acquired pneumonia carries a mortality of less than one percent, hospitalized community-acquired pneumonia has a mortality of five to ten percent, and community-acquired pneumonia requiring intensive care unit admission carries a mortality of twenty to fifty percent. These data highlight the critical importance of accurate severity assessment and appropriate triage.

Multiple risk factors predispose individuals to the development of pneumonia and influence disease severity. Advanced age, particularly above sixty-five years, is associated with increased susceptibility due to immunosenescence, decreased mucociliary clearance, and a higher prevalence of comorbid conditions. Smoking is a major risk factor through its causation of chronic obstructive pulmonary disease and direct impairment of airway defense mechanisms including mucociliary clearance and alveolar macrophage function. Alcohol use predisposes to pneumonia through increased aspiration risk, impaired immune function, and altered upper airway flora. Chronic medical conditions including diabetes mellitus, chronic obstructive pulmonary disease, congestive heart failure, and chronic kidney disease independently increase the risk and severity of pneumonia. Immunocompromise from HIV infection, organ transplantation, chemotherapy, or immunosuppressive medications broadens the potential pathogen spectrum to include opportunistic organisms. Recent hospitalization or healthcare exposure increases the risk of infection with multidrug-resistant organisms.

The pathogenesis of pneumonia involves the entry of pathogens into the lower respiratory tract through several mechanisms, followed by a failure of host defense mechanisms to clear the inoculum. Microaspiration of oropharyngeal secretions is the most common mechanism and occurs even in healthy individuals during sleep, but effective mucociliary clearance and alveolar macrophage function normally prevent infection. Macroaspiration, involving a larger volume of oropharyngeal or gastric contents, is the mechanism underlying aspiration pneumonia and occurs in patients with impaired consciousness, dysphagia, or gastroesophageal reflux. Inhalation of aerosolized pathogens is the mechanism for Legionella pneumophila, respiratory viruses including influenza, and Mycobacterium tuberculosis. Hematogenous spread, in which organisms seed the lungs via the bloodstream, is characteristic of Staphylococcus aureus pneumonia, particularly in the setting of endocarditis or infected intravascular devices. Ultimately, pneumonia develops when the pathogen burden overwhelms the host defense mechanisms, including the cough reflex, mucociliary apparatus, alveolar macrophages, and the adaptive immune response.

<image>Panel A: Flowchart classifying pneumonia by acquisition setting with definitions and timelines: community-acquired (outside hospital), hospital-acquired (48 hours or more after admission), ventilator-associated (48 hours or more after intubation), and aspiration (associated with aspiration event). Panel B: Epidemiological infographic showing CAP incidence rates, hospitalization percentages, and mortality data stratified by outpatient (<1%), inpatient (5-10%), and ICU (20-50%) settings displayed as a stepped pyramid. Panel C: Risk factor diagram showing modifiable and non-modifiable factors including age, smoking, alcohol use, comorbidities (DM, COPD, CHF, CKD), and immunocompromise converging on pneumonia risk. Panel D: Illustration of four pathogenesis mechanisms showing microaspiration of oropharyngeal flora, macroaspiration of gastric contents, inhalation of aerosolized Legionella from water source, and hematogenous seeding of lungs from endocarditis vegetation.</image>

Section 2: Microbiology

The microbiology of community-acquired pneumonia is dominated by a relatively limited number of pathogens, although in a significant proportion of cases no organism is identified. Streptococcus pneumoniae remains the most commonly identified bacterial pathogen in community-acquired pneumonia across all severity levels. Respiratory viruses, including influenza, respiratory syncytial virus, rhinovirus, and SARS-CoV-2, are increasingly recognized as important causes of pneumonia, either as primary pathogens or as co-infections that predispose to secondary bacterial superinfection. Haemophilus influenzae is a common pathogen in patients with chronic obstructive pulmonary disease, while atypical organisms including Mycoplasma pneumoniae and Chlamydophila pneumoniae are more prevalent in younger patients with milder illness. Legionella pneumophila is an important cause of severe community-acquired pneumonia and is associated with travel, exposure to contaminated water systems, and institutional outbreaks. Staphylococcus aureus pneumonia occurs particularly following influenza infection and in intravenous drug users. Notably, no pathogen is identified in forty to sixty percent of community-acquired pneumonia cases despite microbiological testing.

Specific clinical risk factors help predict the likely causative pathogen and guide empiric antibiotic selection. Patients with chronic obstructive pulmonary disease are at increased risk for Haemophilus influenzae and Moraxella catarrhalis due to chronic airway colonization with these organisms. Alcoholism predisposes to Klebsiella pneumoniae, which classically causes a necrotizing pneumonia with "currant jelly" sputum, as well as aspiration pneumonia with anaerobic organisms and severe pneumococcal disease. Post-influenza pneumonia is characteristically complicated by Staphylococcus aureus superinfection, including methicillin-resistant strains, which can cause rapidly progressive necrotizing pneumonia. Structural lung disease, including bronchiectasis and cystic fibrosis, predisposes to colonization and infection with Pseudomonas aeruginosa. Poor dentition and periodontal disease increase the burden of anaerobic organisms in the oropharynx, predisposing to aspiration pneumonia with polymicrobial anaerobic infection. Travel history, particularly stays at hotels or on cruise ships, should raise suspicion for Legionella, which is transmitted through contaminated aerosolized water from cooling towers, hot tubs, and plumbing systems.

Hospital-acquired and ventilator-associated pneumonia have a distinct microbiological profile characterized by a higher prevalence of multidrug-resistant organisms. Pseudomonas aeruginosa is one of the most common causes of ventilator-associated pneumonia and is inherently resistant to many antibiotics. Staphylococcus aureus, including methicillin-resistant strains, is a frequent pathogen in both hospital-acquired and ventilator-associated pneumonia and is associated with significant morbidity. Enterobacteriaceae, including Escherichia coli and Klebsiella pneumoniae, are common gram-negative causes of nosocomial pneumonia and may produce extended-spectrum beta-lactamases that confer resistance to many cephalosporins. Acinetobacter baumannii is a particularly problematic pathogen in intensive care units due to its extreme antimicrobial resistance, environmental persistence, and association with outbreaks. Stenotrophomonas maltophilia is an emerging pathogen in immunocompromised patients, particularly those who have received broad-spectrum antibiotics, and is intrinsically resistant to carbapenems.

Atypical pathogens represent a clinically important group characterized by their intracellular location, lack of a cell wall (in the case of Mycoplasma), and requirement for specific antibiotic classes for effective treatment. Mycoplasma pneumoniae is the most common atypical pathogen, typically affecting young adults and presenting with a gradual onset of nonproductive cough, low-grade fever, and a relatively mild clinical course, although severe cases with complications including encephalitis and hemolytic anemia can occur. Chlamydophila pneumoniae causes a similar mild illness characterized by persistent nonproductive cough, pharyngitis, and hoarseness. Legionella pneumophila, in contrast, frequently causes severe pneumonia with distinctive extrapulmonary features including gastrointestinal symptoms (diarrhea, nausea, vomiting), confusion, and hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion. Because atypical pathogens lack a traditional cell wall or are obligate intracellular organisms, they are not susceptible to beta-lactam antibiotics and require treatment with macrolides, tetracyclines, or fluoroquinolones that achieve adequate intracellular concentrations.

<image>Panel A: Pie chart showing relative frequency of community-acquired pneumonia pathogens including S. pneumoniae, respiratory viruses, H. influenzae, Mycoplasma, Chlamydophila, Legionella, S. aureus, and no pathogen identified (40-60%), with representative microscopic morphologies. Panel B: Clinical risk factor-pathogen association matrix with connecting lines between risk factors (COPD, alcoholism, post-influenza, structural lung disease, poor dentition, travel) and their associated pathogens with descriptive labels. Panel C: Comparison of HAP/VAP microbiology showing Pseudomonas aeruginosa, MRSA, Enterobacteriaceae, Acinetobacter, and Stenotrophomonas with antimicrobial resistance profiles and prevalence in ICU settings. Panel D: Comparative illustration of atypical pathogens showing Mycoplasma (no cell wall, young adult, mild), Chlamydophila (intracellular, persistent cough), and Legionella (water source transmission, severe with GI symptoms and hyponatremia), with their susceptible antibiotic classes.</image>

Section 3: Clinical Presentation

The typical clinical presentation of pneumonia includes a constellation of respiratory and systemic symptoms that develop over hours to days. Cough is the most common symptom, present in eighty to ninety percent of patients, and may be productive of purulent, rust-colored, or blood-tinged sputum. Fever occurs in seventy to eighty percent of cases and may be accompanied by chills and rigors, which are particularly characteristic of pneumococcal pneumonia. Dyspnea is reported in sixty to seventy percent of patients and reflects the impairment of gas exchange caused by alveolar consolidation, inflammation, and ventilation-perfusion mismatch. Pleuritic chest pain, present in thirty to forty percent of cases, is typically sharp, localized, and exacerbated by deep inspiration, reflecting inflammation of the visceral pleura overlying the infected lung parenchyma. The combination of acute onset cough with fever and sputum production in a patient with respiratory distress should immediately raise the clinical suspicion for pneumonia.

The physical examination in pneumonia reveals characteristic findings that reflect the underlying pulmonary consolidation and inflammatory response. Fever may be high-grade with temperatures exceeding thirty-nine degrees Celsius, although it may be absent in elderly or immunocompromised patients. Tachypnea is one of the most sensitive clinical markers of pneumonia and correlates with disease severity. Tachycardia reflects the systemic inflammatory response and may indicate impending hemodynamic compromise when severe. Hypoxemia detected by pulse oximetry is an important indicator of severity and guides the need for supplemental oxygen or escalation of respiratory support. Auscultatory findings over the affected lung include crackles (rales), which indicate fluid-filled alveoli, bronchial breath sounds, which indicate dense consolidation with patent airways transmitting central airway sounds to the periphery, and egophony (E-to-A change), which occurs when consolidated lung tissue transmits voice sounds with altered acoustic properties. Dullness to percussion indicates either consolidation of the underlying lung parenchyma or the presence of a pleural effusion.

Atypical presentations of pneumonia are particularly important to recognize because they may lead to diagnostic delays and increased morbidity. Elderly patients frequently present without classic respiratory symptoms and instead manifest with confusion, altered mental status, falls, functional decline, or decompensation of chronic medical conditions, while fever may be blunted or absent. Immunocompromised patients may have subtle or atypical symptoms due to their impaired ability to mount a robust inflammatory response, and the clinician must maintain a high index of suspicion in this population. Patients infected with atypical pathogens such as Mycoplasma and Chlamydophila often present with a gradual onset of nonproductive cough, low-grade fever, and extrapulmonary symptoms rather than the acute purulent illness associated with typical bacterial pneumonia. Recognition of these atypical presentations is essential for timely diagnosis and appropriate treatment.

Extrapulmonary features associated with specific pathogens provide valuable diagnostic clues that can help guide empiric therapy. Legionella pneumonia is distinguished by prominent gastrointestinal symptoms including diarrhea, nausea, abdominal pain, and vomiting, along with confusion, relative bradycardia, and hyponatremia resulting from inappropriate antidiuretic hormone secretion. Mycoplasma pneumoniae may cause extrapulmonary manifestations including erythema multiforme and other skin rashes, hemolytic anemia due to cold agglutinins, bullous myringitis (hemorrhagic blistering of the tympanic membrane), and neurological complications including encephalitis and Guillain-Barre syndrome. Chlamydophila pneumoniae may present with prominent upper respiratory symptoms including hoarseness and pharyngitis that precede the development of lower respiratory tract involvement. Recognizing these extrapulmonary patterns helps narrow the differential diagnosis, inform diagnostic testing, and guide the selection of targeted antibiotic therapy when specific pathogen-directed treatment is warranted.

<image>Panel A: Clinical illustration of a patient with typical pneumonia showing labeled symptoms including productive cough, high fever with chills, dyspnea with increased respiratory rate, and pleuritic chest pain localized to the affected hemithorax, with frequency percentages annotated. Panel B: Illustration of physical examination findings in pneumonia including auscultation revealing crackles, bronchial breath sounds, and egophony over the area of consolidation, percussion demonstrating dullness, and pulse oximetry showing hypoxemia. Panel C: Comparison of typical versus atypical presentations showing an elderly patient with confusion and falls (no fever), an immunocompromised patient with subtle symptoms, and a young adult with gradual onset dry cough from atypical pathogen. Panel D: Extrapulmonary feature panels showing Legionella with GI symptoms, confusion, and hyponatremia on lab display; Mycoplasma with skin rash, hemolytic anemia on blood smear, and bullous myringitis on otoscopic view; and Chlamydophila with pharyngitis and hoarseness.</image>

Section 4: Diagnosis

The diagnosis of pneumonia requires the integration of clinical symptoms, physical examination findings, and radiographic imaging to establish the presence of lower respiratory tract infection with a new pulmonary infiltrate. The clinical criteria include acute onset of respiratory symptoms such as cough, dyspnea, and sputum production, accompanied by systemic signs including fever, tachycardia, and tachypnea. Physical examination findings of abnormal lung sounds, particularly crackles, bronchial breath sounds, and egophony, provide supportive evidence. However, the diagnosis requires radiographic confirmation with a new infiltrate on chest imaging, as clinical criteria alone have insufficient specificity to distinguish pneumonia from other acute respiratory conditions. The combination of clinical symptoms with a new radiographic infiltrate in the appropriate clinical context establishes the diagnosis and should prompt initiation of appropriate antibiotic therapy.

Chest imaging plays a central role in the diagnosis of pneumonia and provides information about the pattern, extent, and complications of the disease. Lobar consolidation, characterized by a dense, homogeneous opacity involving an entire lobe or segment, is the classic radiographic pattern of typical bacterial pneumonia, particularly pneumococcal disease. An interstitial or reticulonodular pattern, with bilateral, diffuse, non-lobar opacities, is more characteristic of atypical pneumonia caused by Mycoplasma, Chlamydophila, or respiratory viruses. Multilobar involvement indicates severe disease and is associated with a worse prognosis and higher likelihood of requiring intensive care. Cavitation within a pulmonary infiltrate suggests infection with organisms capable of tissue necrosis, including Staphylococcus aureus, Klebsiella pneumoniae, anaerobic organisms, and Mycobacterium tuberculosis. Pleural effusion is present in approximately forty percent of patients hospitalized with community-acquired pneumonia and requires evaluation to exclude complicated parapneumonic effusion or empyema.

Laboratory studies complement clinical and radiographic assessment and help determine disease severity, guide management, and provide microbiological diagnosis. A complete blood count typically reveals leukocytosis with a left shift (neutrophil predominance), although leukopenia indicates a more severe immune response and is an ATS/IDSA minor criterion for intensive care unit admission. A basic metabolic panel assesses renal function (BUN is a component of both CURB-65 and PSI scores) and identifies electrolyte abnormalities. Procalcitonin is a biomarker that is elevated in bacterial infection and may serve as an adjunct in differentiating bacterial from viral pneumonia and guiding antibiotic duration. Serum lactate should be measured when sepsis is suspected, as it serves as a marker of tissue hypoperfusion and guides resuscitation. Blood cultures should be obtained in all hospitalized patients prior to antibiotic administration, and sputum cultures are indicated when a quality specimen can be obtained, defined as fewer than ten squamous epithelial cells and more than twenty-five polymorphonuclear cells per low-power field.

Microbiological studies are essential for pathogen identification and antibiotic susceptibility testing, particularly in hospitalized and severely ill patients. Blood cultures should be drawn from two separate sites prior to antibiotic administration and are positive in approximately five to fifteen percent of hospitalized community-acquired pneumonia cases. Sputum culture and Gram stain are most useful when obtained from a quality specimen in the setting of severe community-acquired pneumonia. Urinary antigen testing for Legionella pneumophila serogroup one and Streptococcus pneumoniae provides rapid pathogen identification and is recommended in severe community-acquired pneumonia. Respiratory viral panels, including testing for influenza and SARS-CoV-2, should be obtained when viral pneumonia is suspected, as identification of a viral etiology may allow for antiviral therapy and avoidance of unnecessary antibiotics. Bronchoscopy with bronchoalveolar lavage is reserved for immunocompromised patients or those who fail to improve on empiric therapy, providing direct sampling of the lower respiratory tract for culture, cytology, and specialized staining.

<image>Panel A: Diagnostic algorithm flowchart showing clinical criteria (symptoms and signs) combined with radiographic confirmation (new infiltrate on chest imaging) leading to the diagnosis of pneumonia, with branch points for atypical presentations and alternative diagnoses. Panel B: Chest radiograph comparison panel showing lobar consolidation (typical bacterial), bilateral interstitial infiltrates (atypical or viral), multilobar involvement (severe pneumonia), cavitary lesion (S. aureus or Klebsiella), and pleural effusion (parapneumonic). Panel C: Laboratory test display showing CBC with leukocytosis and left shift, BMP with elevated BUN, elevated procalcitonin level, elevated lactate, and blood culture bottles with timing annotation. Panel D: Microbiological testing panel showing blood culture collection from two sites, sputum Gram stain under microscopy, urinary antigen test strips for Legionella and pneumococcus, respiratory viral panel results, and bronchoscopy with BAL procedure illustration.</image>

Section 5: Severity Assessment

The CURB-65 score is a simple, validated bedside tool used to assess the severity of community-acquired pneumonia and guide disposition decisions. The acronym represents five clinical variables, each scored as one point: Confusion (new-onset disorientation to person, place, or time), Urea greater than nineteen milligrams per deciliter (or seven millimoles per liter), Respiratory rate of thirty or more breaths per minute, Blood pressure with systolic less than ninety or diastolic less than or equal to sixty millimeters of mercury, and age sixty-five years or older. A score of zero to one indicates low-risk disease appropriate for outpatient management, a score of two represents intermediate risk warranting consideration of hospital admission or close outpatient follow-up, and a score of three or greater indicates high-risk disease requiring hospitalization with consideration of intensive care unit admission. The simplicity of CURB-65 makes it ideal for rapid bedside assessment, although it should be used as an adjunct to clinical judgment rather than as the sole determinant of disposition.

The Pneumonia Severity Index, also known as the PORT score, is a more comprehensive severity assessment tool that has been extensively validated for predicting thirty-day mortality in community-acquired pneumonia. The score incorporates demographic variables (age, sex, nursing home residence), comorbid conditions (cancer, liver disease, congestive heart failure, renal disease, and cerebrovascular disease), physical examination findings (altered mental status, respiratory rate, blood pressure, temperature, and heart rate), and laboratory and imaging data (arterial pH, blood urea nitrogen, sodium, glucose, hematocrit, partial pressure of oxygen, and the presence of pleural effusion). Patients are categorized into five risk classes: class one and two patients are low risk and can typically be managed as outpatients, class three patients are intermediate risk and may benefit from a period of observation, and class four and five patients are high risk and require inpatient management. Although more accurate than CURB-65, the PSI is more complex to calculate and may underestimate severity in young patients without comorbidities.

The American Thoracic Society and Infectious Diseases Society of America have established specific criteria for intensive care unit admission in community-acquired pneumonia. The major criteria are septic shock requiring vasopressor support and respiratory failure requiring invasive mechanical ventilation, and the presence of either major criterion alone mandates intensive care unit admission. The minor criteria include respiratory rate of thirty or more breaths per minute, PaO2/FiO2 ratio of two hundred fifty or less, multilobar infiltrates on chest imaging, new-onset confusion or disorientation, blood urea nitrogen of twenty or more milligrams per deciliter, leukopenia with white blood cell count below four thousand cells per microliter, thrombocytopenia with platelet count below one hundred thousand per microliter, hypothermia with core temperature below thirty-six degrees Celsius, and hypotension requiring aggressive fluid resuscitation. The presence of one major criterion or three or more minor criteria indicates the need for intensive care unit admission or a higher level of monitoring.

Selecting the appropriate severity assessment tool depends on the clinical context and the decision that needs to be made. CURB-65 is best suited for rapid bedside assessment and initial triage decisions, particularly in the emergency department or urgent care setting, due to its simplicity and ease of calculation without laboratory data (the CRB-65 variant excludes urea). The Pneumonia Severity Index is the most thoroughly validated tool for predicting mortality and is particularly useful for identifying low-risk patients who can be safely managed as outpatients, thereby avoiding unnecessary hospitalization. The ATS/IDSA criteria are specifically designed to identify patients who require intensive care unit level care and should be applied to all patients presenting with severe community-acquired pneumonia. Clinical judgment remains an essential complement to all scoring tools, as factors not captured by the scores, such as social circumstances, reliability of follow-up, patient preferences, and the presence of exacerbating conditions, must be considered in the final disposition decision.

<image>Panel A: CURB-65 scoring diagram showing the five components (Confusion, Urea, Respiratory rate, Blood pressure, Age 65+) with point assignments, and three disposition pathways: outpatient (score 0-1), consider admission (score 2), and hospitalize/ICU (score 3-5). Panel B: Pneumonia Severity Index calculator layout showing demographic variables, comorbidity points, physical examination findings, and laboratory/imaging data with final risk class assignment (I-V) and corresponding mortality percentages. Panel C: ATS/IDSA ICU admission criteria displayed as major criteria (septic shock, respiratory failure requiring intubation) and nine minor criteria with the rule of one major or three or more minor criteria for ICU admission. Panel D: Comparative summary of all three tools showing CURB-65 (simple, bedside, triage), PSI (comprehensive, validated, outpatient identification), and ATS/IDSA (ICU decision), with a clinical judgment overlay emphasizing the importance of physician assessment alongside standardized scores.</image>

Section 6: Community-Acquired Pneumonia Treatment

Outpatient treatment of community-acquired pneumonia is appropriate for patients identified as low risk by severity assessment tools and clinical judgment. For previously healthy patients without significant comorbidities or recent antibiotic use, monotherapy with amoxicillin is the preferred first-line regimen, with doxycycline or a macrolide (azithromycin or clarithromycin) as alternatives, noting that macrolide resistance rates should be below twenty-five percent in the community for macrolide monotherapy to be appropriate. For patients with comorbidities such as chronic heart, lung, liver, or renal disease, diabetes mellitus, alcoholism, or recent antibiotic use within the past three months, combination therapy with amoxicillin-clavulanate or a cephalosporin plus a macrolide is recommended, or alternatively a respiratory fluoroquinolone (levofloxacin or moxifloxacin) as monotherapy. The duration of outpatient therapy is a minimum of five days, with the criteria for discontinuation being clinical improvement, resolution of fever for at least forty-eight hours, and absence of more than one sign of clinical instability.

Inpatient treatment of community-acquired pneumonia on a general medical ward requires broader antimicrobial coverage than outpatient therapy. The standard regimen is a beta-lactam antibiotic, most commonly ceftriaxone, combined with a macrolide such as azithromycin, providing coverage against both typical bacterial pathogens and atypical organisms. An alternative regimen for patients with contraindications to macrolides or beta-lactams is a respiratory fluoroquinolone (levofloxacin or moxifloxacin) as monotherapy, which provides broad coverage against typical and atypical pathogens. Acceptable beta-lactam options include ceftriaxone, cefotaxime, and ampicillin-sulbactam, each providing adequate coverage against Streptococcus pneumoniae and common gram-negative pathogens. The minimum duration of inpatient therapy is five days, provided the patient has achieved clinical stability, defined as resolution of fever for at least forty-eight hours, improving symptoms, ability to take oral medications, and a normal or improving white blood cell count.

Patients admitted to the intensive care unit with severe community-acquired pneumonia require the most aggressive empiric antibiotic coverage. The standard ICU regimen is a beta-lactam antibiotic (ceftriaxone, cefotaxime, or ampicillin-sulbactam) combined with a macrolide (azithromycin), providing coverage against the full spectrum of typical and atypical pathogens including Legionella. An alternative to the macrolide component is a respiratory fluoroquinolone combined with the beta-lactam. Patients with risk factors for Pseudomonas aeruginosa infection, including structural lung disease, prior Pseudomonas infection, and recent broad-spectrum antibiotic exposure, require an anti-pseudomonal beta-lactam (piperacillin-tazobactam, cefepime, or meropenem) combined with an aminoglycoside and a macrolide to ensure double coverage of Pseudomonas and continued atypical coverage. When methicillin-resistant Staphylococcus aureus is suspected, such as after influenza infection or in patients with cavitary infiltrates, vancomycin or linezolid should be added to the regimen.

The duration of antibiotic therapy for community-acquired pneumonia has been shortened based on evidence demonstrating that shorter courses are as effective as longer courses for uncomplicated disease. Uncomplicated community-acquired pneumonia should be treated for a minimum of five days, with the additional requirement that the patient must be afebrile for at least forty-eight hours and have no more than one sign of clinical instability before antibiotics are discontinued. Complicated pneumonia, including cases with empyema, lung abscess, or bacteremia with certain organisms, requires longer treatment durations individualized to the clinical response. The transition from intravenous to oral antibiotics (step-down therapy) should occur as soon as the patient is clinically stable, able to tolerate oral intake, and has a functioning gastrointestinal tract, which typically occurs within forty-eight to seventy-two hours. Procalcitonin-guided antibiotic duration has shown promise in reducing unnecessary antibiotic exposure and may be used as an adjunct to clinical assessment in determining when to discontinue therapy.

<image>Panel A: Outpatient treatment algorithm showing two pathways: healthy patients without comorbidities (amoxicillin, doxycycline, or macrolide monotherapy) and patients with comorbidities (amoxicillin-clavulanate plus macrolide or respiratory fluoroquinolone monotherapy), with 5-day minimum duration annotated. Panel B: Inpatient non-ICU treatment diagram showing standard regimen (ceftriaxone plus azithromycin) and alternative (respiratory fluoroquinolone monotherapy), with beta-lactam options and 5-day minimum duration with clinical stability criteria. Panel C: ICU treatment regimen showing standard (beta-lactam plus macrolide), Pseudomonas coverage (anti-pseudomonal beta-lactam plus aminoglycoside plus macrolide), and MRSA coverage addition (vancomycin or linezolid), with dosing annotations. Panel D: Duration of therapy decision tree showing uncomplicated CAP (5 days minimum), complicated CAP (extended), IV-to-oral step-down criteria, and procalcitonin-guided duration with serial level measurements.</image>

Section 7: Hospital-Acquired and Ventilator-Associated Pneumonia Treatment

Empiric antibiotic coverage for hospital-acquired and ventilator-associated pneumonia must account for the high prevalence of multidrug-resistant organisms in the nosocomial setting. The empiric regimen should include coverage for Pseudomonas aeruginosa, which is one of the most common and clinically important pathogens in this setting. Methicillin-resistant Staphylococcus aureus coverage is required because MRSA is a frequent cause of both hospital-acquired and ventilator-associated pneumonia. Gram-negative Enterobacteriaceae, including Escherichia coli and Klebsiella pneumoniae, must also be covered, and the local institutional antibiogram should guide the selection of agents based on known resistance patterns. Risk stratification based on prior culture data, length of hospitalization, recent antibiotic exposure, and institutional resistance rates helps determine whether broad empiric coverage for multidrug-resistant organisms is needed or whether a narrower regimen may be appropriate.

Standard empiric regimens for hospital-acquired and ventilator-associated pneumonia combine an anti-pseudomonal beta-lactam with MRSA coverage and, in some cases, additional gram-negative coverage. Anti-pseudomonal beta-lactam options include piperacillin-tazobactam, cefepime, and meropenem, each providing broad gram-negative coverage including activity against Pseudomonas. When the risk for multidrug-resistant gram-negative organisms is elevated based on institutional resistance data or patient-specific risk factors, the addition of a second gram-negative agent such as an aminoglycoside (tobramycin, amikacin) or a fluoroquinolone (ciprofloxacin, levofloxacin) provides double coverage to maximize the likelihood of adequate empiric therapy. MRSA coverage is provided by either vancomycin or linezolid, both of which are effective against methicillin-resistant strains. The recommended duration of therapy for uncomplicated hospital-acquired and ventilator-associated pneumonia is seven days, as studies have demonstrated that shorter courses are as effective as longer courses and are associated with fewer antibiotic-related complications.

Risk factors for multidrug-resistant organisms in nosocomial pneumonia should be systematically assessed to guide the breadth of empiric coverage. Receipt of intravenous antibiotics within the preceding ninety days is a major risk factor for colonization and infection with resistant organisms. Prior colonization or infection with specific resistant organisms, particularly MRSA, extended-spectrum beta-lactamase-producing Enterobacteriaceae, or Pseudomonas, significantly increases the probability of the same organism causing the current infection. Structural lung disease, including bronchiectasis and cystic fibrosis, predisposes to chronic Pseudomonas colonization and infection. High institutional intensive care unit resistance rates, as documented by the local antibiogram, indicate that empiric coverage should be broader to ensure adequate initial therapy. These risk factors must be weighed individually and collectively when designing the empiric antibiotic regimen.

De-escalation of empiric antibiotics is a cornerstone of antibiotic stewardship in nosocomial pneumonia and should be pursued aggressively once culture and susceptibility results become available. Culture-directed narrowing of therapy ensures that the patient receives the most targeted effective antibiotic while minimizing unnecessary broad-spectrum exposure that promotes resistance and Clostridioides difficile infection. If respiratory cultures are negative for MRSA and the patient is clinically improving, vancomycin or linezolid should be discontinued. If Pseudomonas is not isolated, the anti-pseudomonal beta-lactam can be narrowed to a less broad-spectrum agent. Clinical improvement, assessed by resolution of fever, decreasing white blood cell count, improving oxygenation, and reduction in purulent secretions, may support shortening the duration of therapy below the standard seven days, with procalcitonin serving as a potential biomarker to guide this decision.

<image>Panel A: Empiric coverage framework for HAP/VAP showing three required coverage targets (Pseudomonas, MRSA, gram-negative Enterobacteriaceae) with antibiotic options for each target and the role of the institutional antibiogram in guiding selection. Panel B: Empiric regimen options diagram showing anti-pseudomonal beta-lactam choices (piperacillin-tazobactam, cefepime, meropenem), MRSA coverage options (vancomycin, linezolid), and additional gram-negative agents (aminoglycosides, fluoroquinolones) for MDR risk. Panel C: MDR risk factor checklist including prior IV antibiotics within 90 days, prior colonization with resistant organisms, structural lung disease, and high institutional resistance rates, with risk-based coverage recommendations. Panel D: De-escalation pathway showing initial broad empiric coverage narrowed based on culture results: MRSA negative (stop vancomycin), no Pseudomonas (narrow beta-lactam), susceptibility-guided final regimen, with clinical improvement and procalcitonin guiding duration.</image>

Section 8: Aspiration Pneumonia

Aspiration-related pulmonary syndromes encompass two distinct but frequently overlapping clinical entities. Aspiration pneumonitis is a chemical injury to the lung parenchyma caused by aspiration of sterile gastric contents, resulting in an inflammatory response without primary bacterial infection. Aspiration pneumonia, in contrast, is a true infectious process caused by aspiration of oropharyngeal secretions containing pathogenic bacteria into the lower respiratory tract. In clinical practice, these two entities often overlap because chemical injury from aspiration pneumonitis impairs local host defenses and predisposes to secondary bacterial infection. The distinction is clinically relevant because aspiration pneumonitis may resolve with supportive care alone, while aspiration pneumonia requires antibiotic therapy. However, because of the frequent overlap and difficulty in distinguishing the two entities at presentation, antibiotics are typically initiated when aspiration is suspected and clinical features are consistent with pneumonia.

Multiple risk factors predispose patients to aspiration events and the subsequent development of aspiration pneumonia. Dysphagia, whether from stroke, neurodegenerative disease, esophageal motility disorders, or head and neck malignancies, is one of the most common risk factors and impairs the protective coordination of swallowing. Altered consciousness from any cause, including sedation, general anesthesia, seizures, alcohol intoxication, and drug overdose, suppresses the cough reflex and protective airway mechanisms, allowing aspiration of oropharyngeal contents. Gastroesophageal reflux disease predisposes to aspiration of gastric contents, particularly in the recumbent position. Poor dentition and periodontal disease increase the bacterial burden of the oropharynx, particularly with anaerobic organisms, increasing the pathogenic potential of aspirated material. The presence of nasogastric or enteral feeding tubes, while intended to provide nutrition, paradoxically increases aspiration risk by promoting gastroesophageal reflux, impairing lower esophageal sphincter function, and serving as a conduit for colonized secretions.

The microbiology of aspiration pneumonia varies based on the setting of acquisition. Community-acquired aspiration pneumonia is primarily caused by oral anaerobes, including Prevotella, Fusobacterium, and Bacteroides species, along with streptococcal species from the normal oropharyngeal flora. Hospital-acquired aspiration pneumonia has a broader pathogen spectrum that additionally includes gram-negative organisms such as Pseudomonas aeruginosa and Enterobacteriaceae, as well as Staphylococcus aureus, reflecting the altered oropharyngeal colonization that occurs during hospitalization. Most cases of aspiration pneumonia are polymicrobial, involving a mixture of aerobic and anaerobic organisms. The recognition of the polymicrobial nature of aspiration pneumonia is important for selecting appropriate antibiotic coverage that addresses both aerobic and anaerobic components of the infection.

Treatment of aspiration pneumonia is guided by the setting of acquisition and the severity of illness. Community-acquired aspiration pneumonia is appropriately treated with amoxicillin-clavulanate, which provides coverage against oral anaerobes and streptococcal species, or alternatively with clindamycin for patients with penicillin allergy. Hospital-acquired aspiration pneumonia requires broader coverage with piperacillin-tazobactam or a carbapenem (meropenem or imipenem-cilastatin), which provide coverage against nosocomial gram-negative organisms, anaerobes, and many gram-positive pathogens. MRSA coverage with vancomycin or linezolid should be added when risk factors for MRSA are present, including prior MRSA colonization, recent hospitalization, or residence in a healthcare facility with high MRSA prevalence. The duration of therapy is typically seven days for uncomplicated aspiration pneumonia, with longer courses required when complications such as lung abscess or empyema develop. Prevention strategies, including dysphagia screening with formal swallow evaluation, aspiration precautions (head-of-bed elevation, oral care), and judicious use of sedation, are critical for reducing the incidence of aspiration pneumonia.

<image>Panel A: Comparison diagram of aspiration pneumonitis versus aspiration pneumonia showing the pathophysiology of each: chemical injury from sterile gastric acid (pneumonitis) versus bacterial infection from oropharyngeal organisms (pneumonia), with their clinical overlap zone. Panel B: Illustration of aspiration risk factors showing a patient with multiple risk factors labeled: dysphagia from stroke (brain with infarct), altered consciousness (medication bottles), GERD (reflux arrows), poor dentition (dental decay), and nasogastric tube placement. Panel C: Microbiology comparison showing community-acquired aspiration (oral anaerobes: Prevotella, Fusobacterium, Bacteroides, and streptococci) versus hospital-acquired aspiration (adding Pseudomonas, Enterobacteriaceae, and S. aureus to the anaerobic organisms). Panel D: Treatment algorithm branching from community-acquired (amoxicillin-clavulanate or clindamycin) versus hospital-acquired (piperacillin-tazobactam or carbapenem plus or minus MRSA coverage), with duration annotations and prevention strategies listed.</image>

Section 9: Treatment Failure and Complications

Treatment failure in pneumonia is defined by either early deterioration (within seventy-two hours of antibiotic initiation) or late failure to improve (beyond seventy-two hours of therapy). Early treatment failure manifests as clinical deterioration with worsening respiratory status, increasing oxygen requirements, hemodynamic instability, or progression of radiographic infiltrates despite appropriate empiric antibiotic therapy. Late treatment failure is characterized by the absence of expected clinical improvement, including persistent fever, continued leukocytosis, and failure to improve radiographically. The differential diagnosis of treatment failure includes incorrect initial diagnosis (the infiltrate may represent a non-infectious process such as pulmonary embolism, malignancy, organizing pneumonia, or eosinophilic pneumonia), infection with a resistant or unusual organism not covered by the empiric regimen, and the development of a complication such as empyema, lung abscess, or superinfection.

A systematic workup is essential when treatment failure is identified. Repeat chest imaging, including computed tomography if not already performed, should be obtained to evaluate for complications such as abscess formation, empyema, or progression of disease, and to identify alternative diagnoses. Repeat microbiological cultures, including blood cultures and sputum culture, should be obtained to identify resistant organisms or pathogens not covered by the initial empiric regimen. Bronchoscopy with bronchoalveolar lavage is indicated in immunocompromised patients or when non-invasive testing has failed to yield a diagnosis, as it provides direct sampling for bacterial, fungal, mycobacterial, and viral cultures, as well as cytology. Alternative diagnoses that should be considered include pulmonary embolism, which can present with similar symptoms and radiographic findings, malignancy with post-obstructive pneumonia, acute eosinophilic pneumonia, organizing pneumonia, and acute respiratory distress syndrome.

Parapneumonic effusion and empyema are important complications of pneumonia that significantly impact management and outcomes. A simple parapneumonic effusion is a small, free-flowing, sterile, exudative pleural effusion that typically resolves with appropriate antibiotic therapy alone. A complicated parapneumonic effusion is characterized by a pleural fluid pH below 7.2, glucose below sixty milligrams per deciliter, and lactate dehydrogenase above one thousand international units per liter, indicating significant pleural inflammation and a high risk of progression to empyema if not drained. Empyema is defined by the presence of frank pus in the pleural space or a positive pleural fluid culture and represents a surgical emergency requiring drainage. Management of complicated parapneumonic effusion and empyema requires chest tube drainage, which may be supplemented by intrapleural fibrinolytics (tissue plasminogen activator with deoxyribonuclease) to break up loculations, and surgical decortication may be necessary for inadequately drained collections.

Other major complications of pneumonia include lung abscess, acute respiratory distress syndrome, sepsis, and respiratory failure requiring mechanical ventilation. Lung abscess presents as a cavitary lesion on imaging, often with an air-fluid level, and is characterized clinically by fever, weight loss, and foul-smelling sputum suggesting anaerobic infection. Acute respiratory distress syndrome may develop as a consequence of the intense inflammatory response triggered by severe pneumonia and is characterized by bilateral pulmonary infiltrates, refractory hypoxemia, and a PaO2/FiO2 ratio below three hundred. Sepsis, defined as life-threatening organ dysfunction caused by a dysregulated host response to infection, complicates a significant proportion of hospitalized pneumonia cases and requires aggressive management with fluids, antibiotics, and vasopressors as outlined in sepsis guidelines. Respiratory failure requiring invasive mechanical ventilation is the most severe pulmonary complication and necessitates lung-protective ventilation strategies with low tidal volumes and appropriate positive end-expiratory pressure.

<image>Panel A: Timeline diagram showing early treatment failure (within 72 hours) versus late treatment failure (beyond 72 hours), with clinical indicators at each stage including worsening vital signs, persistent fever, and progressive radiographic infiltrates, alongside differential diagnosis lists. Panel B: Systematic workup algorithm for treatment failure showing repeat imaging (CT chest), repeat cultures (blood and sputum), bronchoscopy with BAL (immunocompromised), and alternative diagnoses to consider (PE, malignancy, organizing pneumonia, ARDS). Panel C: Cross-sectional chest diagram showing progression from simple parapneumonic effusion (small, free-flowing) to complicated parapneumonic effusion (pH <7.2, low glucose) to empyema (frank pus), with corresponding management at each stage from antibiotics alone to chest tube drainage. Panel D: Complications panel showing four quadrants: lung abscess (CT image with cavity and air-fluid level), ARDS (bilateral infiltrates on CXR with ventilator settings), sepsis (organ dysfunction diagram), and respiratory failure (intubated patient with ventilator parameters).</image>

Section 10: Prevention and Special Considerations

Vaccination is the most effective preventive strategy against pneumonia and should be recommended for all eligible patients. Pneumococcal vaccination with either PCV15 or PCV20 conjugate vaccines is recommended for all adults aged sixty-five years and older and for younger adults with immunocompromising conditions, chronic medical diseases, or other risk factors, with PPSV23 administered sequentially after PCV15 for those who receive the older conjugate vaccine. Annual influenza vaccination is recommended for all adults and significantly reduces the risk of influenza-related pneumonia and its complications, including secondary bacterial superinfection. COVID-19 vaccination, administered according to current guidelines, has dramatically reduced the incidence of severe pneumonia requiring hospitalization and intensive care. Respiratory syncytial virus vaccination has been approved for adults aged sixty years and older, providing a new tool for prevention of RSV-related lower respiratory tract disease in older adults.

Prevention of pneumonia in the hospital setting focuses on reducing the risk of hospital-acquired and ventilator-associated infection through evidence-based bundles. Ventilator-associated pneumonia prevention bundles include elevation of the head of the bed to thirty to forty-five degrees to reduce aspiration risk, regular oral care with chlorhexidine, daily sedation vacation to assess readiness for extubation, and daily assessment of readiness for spontaneous breathing trials. Aspiration precautions, including formal swallowing evaluation for patients with stroke or altered consciousness, are critical for preventing aspiration pneumonia. Hand hygiene and contact precautions are fundamental infection control measures that prevent horizontal transmission of respiratory pathogens between patients and from healthcare workers. Early mobilization of hospitalized patients reduces the risk of pneumonia and other complications by preventing atelectasis, improving mucociliary clearance, and maintaining respiratory muscle strength.

Immunocompromised patients with pneumonia require special diagnostic and therapeutic considerations due to their expanded pathogen spectrum and atypical presentations. The differential diagnosis in immunocompromised patients extends beyond typical bacterial pathogens to include Pneumocystis jirovecii (particularly in HIV with CD4 count below two hundred or patients on chronic immunosuppression), fungal infections including Aspergillus and Cryptococcus, viral reactivation including cytomegalovirus, and mycobacterial disease. More extensive diagnostic workup is warranted, including bronchoscopy with bronchoalveolar lavage for culture, cytology, and specialized staining (Gomori methenamine silver for Pneumocystis, galactomannan for Aspergillus). Empiric antibiotic coverage should be broader initially to address the wider range of potential pathogens until a specific diagnosis is established. Prophylaxis against Pneumocystis pneumonia with trimethoprim-sulfamethoxazole is indicated for patients with HIV and CD4 counts below two hundred, organ transplant recipients, and patients receiving high-dose immunosuppressive therapy.

Prognostic factors in pneumonia help guide clinical decision-making and inform discussions with patients and families. Advanced age is independently associated with increased mortality from pneumonia, with case fatality rates rising substantially in patients over seventy-five years of age. Comorbid conditions, including chronic obstructive pulmonary disease, congestive heart failure, diabetes mellitus, chronic kidney disease, and malignancy, each independently increase the risk of complications and death. Bacteremia, present in approximately five to fifteen percent of hospitalized community-acquired pneumonia cases, is associated with a significantly higher mortality rate and predicts a more complicated clinical course. Intensive care unit admission and the need for mechanical ventilation or vasopressor support are strong markers of disease severity and carry substantially higher mortality. The time to first antibiotic dose is a modifiable prognostic factor, with evidence demonstrating that earlier antibiotic administration is associated with improved outcomes, supporting the practice of initiating empiric therapy promptly once the clinical diagnosis is established.

<image>Panel A: Vaccination schedule infographic showing pneumococcal vaccines (PCV15/PCV20 and PPSV23) with age and risk-based indications, annual influenza vaccine, COVID-19 vaccine, and RSV vaccine for adults 60 and older, with timeline and eligibility annotations. Panel B: Hospital prevention bundle illustration showing VAP prevention measures: head-of-bed elevation at 30-45 degrees, oral care with chlorhexidine, sedation vacation assessment, spontaneous breathing trial, aspiration precautions with swallow evaluation, hand hygiene, and early mobilization. Panel C: Immunocompromised patient diagnostic pathway showing expanded differential (Pneumocystis, Aspergillus, CMV, mycobacteria), advanced diagnostics (BAL with special stains, galactomannan, beta-D-glucan), broader empiric coverage, and PCP prophylaxis indications. Panel D: Prognostic factor display showing age-mortality curve, comorbidity impact on outcomes, bacteremia mortality comparison, ICU admission outcomes, and time-to-antibiotics relationship with survival, presented as annotated graphs and data displays.</image>

Summary

• CAP develops outside the hospital; HAP develops 48 or more hours after admission; VAP develops 48 or more hours after intubation
• Streptococcus pneumoniae is the most commonly identified CAP pathogen; 40-60% of cases have no identified organism
• Diagnosis requires clinical symptoms plus a new radiographic infiltrate; cultures should be obtained in hospitalized patients
• Severity assessment tools (CURB-65, PSI) guide disposition; ATS/IDSA criteria identify patients needing ICU admission
• Inpatient CAP: beta-lactam plus macrolide is the standard regimen; minimum 5-day duration if clinically stable
• HAP/VAP: anti-pseudomonal and MRSA coverage with de-escalation guided by culture results
• Aspiration pneumonia involves anaerobic coverage; prevention focuses on addressing modifiable risk factors
• Treatment failure requires systematic workup including repeat imaging, cultures, and consideration of alternative diagnoses
• Complications include parapneumonic effusion (drain if complicated or empyema), lung abscess, ARDS, and sepsis
• Prevention strategies include pneumococcal and influenza vaccination, VAP prevention bundles, and aspiration precautions

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown